Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Appropriate and effective management of rheumatoid arthritis.

Literature DB >> 15140767

Appropriate and effective management of rheumatoid arthritis.

Abstract

Early referral (at <3 months) and early DMARD treatment enable the course of RA to be changed. Once the disease has become aggressive it is much harder to treat and improvements will not be as great as they would have been with earlier treatment. The latest strategies and treatments enable remission to be achieved in many more patients than formerly.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2004 PMID： 15140767 PMCID： PMC1755045 DOI： 10.1136/ard.2003.011395

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

36 in total

Review 1. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.

Authors: J F Fries
Journal: Ann Rheum Dis Date: 1999-11 Impact factor: 19.103

Review 2. Future prospects for anti-cytokine treatment.

Authors: M Feldmann; J Miotla; E Paleolog; R Williams; A M Malfait; P Taylor; F M Brennan; R N Maini
Journal: Ann Rheum Dis Date: 2000-11 Impact factor: 19.103

3. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.

Authors: L R Lard; H Visser; I Speyer; I E vander Horst-Bruinsma; A H Zwinderman; F C Breedveld; J M Hazes
Journal: Am J Med Date: 2001-10-15 Impact factor: 4.965

4. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors: J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

5. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors: P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal: N Engl J Med Date: 2000-11-30 Impact factor: 91.245

6. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.

Authors: D Krause; B Schleusser; G Herborn; R Rau
Journal: Arthritis Rheum Date: 2000-01

7. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

Authors: M Kosinski; S Z Zhao; S Dedhiya; J T Osterhaus; J E Ware
Journal: Arthritis Rheum Date: 2000-07

8. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.

Authors: E Yelin; L A Wanke
Journal: Arthritis Rheum Date: 1999-06

9. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression.

Authors: M Neidhart; J Rethage; S Kuchen; P Künzler; R M Crowl; M E Billingham; R E Gay; S Gay
Journal: Arthritis Rheum Date: 2000-12

Review 10. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.

Authors: Josef S Smolen; Roberto Caporali; Thomas Doerner; Bruno Fautrel; Fabrizio Benedetti; Burkhard Pieper; Minjun Jang
Journal: RMD Open Date: 2021-06

Appropriate and effective management of rheumatoid arthritis.

Review 1. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.

Review 2. Future prospects for anti-cytokine treatment.

3. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.

4. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

5. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

6. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis.

7. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.

8. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.

9. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression.

10. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis.

1. [Are "biologics" in the treatment of rheumatoid arthritis really cost effective?].

2. Personal attributes as determinants of timely care in rheumatoid arthritis.

3. USPIO-enhanced magnetic resonance imaging of the knee in asymptomatic volunteers.

4. Creative trial design in RA: optimizing patient outcomes.

Review 5. Reflections on 'older' drugs: learning new lessons in rheumatology.

6. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

Review 7. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Review 8. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.

Review 9. Induction of remission in rheumatoid arthritis: criteria and opportunities.

Review 10. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.